Should I buy or sell Aethlon Medical stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aethlon Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AEMD shares. View AEMD analyst ratings or view top-rated stocks .

What is Aethlon Medical's stock price target for 2024?

1 analysts have issued 1-year price targets for Aethlon Medical's stock. Their AEMD share price targets range from $23.00 to $23.00. On average, they expect the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 995.2% from the stock's current price. View analysts price targets for AEMD or view top-rated stocks among Wall Street analysts .

How have AEMD shares performed in 2023?

Aethlon Medical's stock was trading at $2.7540 at the start of the year. Since then, AEMD stock has decreased by 23.7% and is now trading at $2.10. View the best growth stocks for 2023 here .

Are investors shorting Aethlon Medical?

Aethlon Medical saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 127,500 shares, an increase of 26.5% from the October 31st total of 100,800 shares. Based on an average trading volume of 16,100 shares, the short-interest ratio is presently 7.9 days. Currently, 5.3% of the shares of the stock are sold short. View Aethlon Medical's Short Interest .

When is Aethlon Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our AEMD earnings forecast .

How were Aethlon Medical's earnings last quarter?

Aethlon Medical, Inc. (NASDAQ:AEMD) announced its quarterly earnings results on Thursday, August, 10th. The medical equipment provider reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.10. During the same quarter last year, the business earned ($1.90) earnings per share.

When did Aethlon Medical's stock split?

Aethlon Medical shares reverse split on the morning of Thursday, October 5th 2023. The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Aethlon Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Amarin (AMRN) , Nokia Oyj (NOK) , Vaxart (VXRT) , VBI Vaccines (VBIV) , Nabriva Therapeutics (NBRV) , CRISPR Therapeutics (CRSP) , Novavax (NVAX) , Organigram (OGI) , AT&T (T) and Aurora Cannabis (ACB) .

Who are Aethlon Medical's major shareholders?

Aethlon Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Aethlon Medical?

Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Aethlon Medical Stock Price, News & Analysis (NASDAQ:AEMD)

$2.19

+0.09 (+4.29%)

(As of 09:30 AM ET)

Compare

Today's Range: $2.19
▼
$2.19
50-Day Range: $1.42
▼
$2.29
52-Week Range: $1.40
▼
$8.70

Volume: 2,037 shs
Average Volume: 63,240 shs
Market Capitalization: $5.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.00

Aethlon Medical MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 995.2% Upside
$23.00 Price Target
Short Interest: Bearish
5.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($5.34) to ($5.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Aethlon Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.00, Aethlon Medical has a forecasted upside of 995.2% from its current price of $2.10.
Amount of Analyst Coverage
Aethlon Medical has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.25% of the float of Aethlon Medical has been sold short.
Short Interest Ratio / Days to Cover
Aethlon Medical has a short interest ratio ("days to cover") of 7.9.
Change versus previous month
Short interest in Aethlon Medical has recently increased by 26.49%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aethlon Medical does not currently pay a dividend.
Dividend Growth
Aethlon Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AEMD.

1.6

News and Social Media Coverage

News Sentiment
Aethlon Medical has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aethlon Medical this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Aethlon Medical to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aethlon Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Aethlon Medical is held by insiders.
Percentage Held by Institutions
Only 3.02% of the stock of Aethlon Medical is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aethlon Medical are expected to decrease in the coming year, from ($5.34) to ($5.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aethlon Medical is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aethlon Medical is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aethlon Medical has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aethlon Medical Stock (NASDAQ:AEMD)

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.

AEMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AEMD Stock News Headlines

November 30, 2023 | americanbankingnews.com

Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Large Increase in Short Interest

November 28, 2023 | americanbankingnews.com

Aethlon Medical (NASDAQ:AEMD) Stock Crosses Below Two Hundred Day Moving Average of $2.82

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

November 28, 2023 | americanbankingnews.com

Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

November 18, 2023 | markets.businessinsider.com

Maxim Group Keeps Their Hold Rating on Aethlon Medical (AEMD)

November 16, 2023 | finance.yahoo.com

AEMD: Expect Focus on Oncology Studies; Cost Containment Efforts

November 16, 2023 | finance.yahoo.com

Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call Transcript

November 14, 2023 | finance.yahoo.com

Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

November 13, 2023 | benzinga.com

A Preview Of Aethlon Medical's Earnings

November 13, 2023 | finance.yahoo.com

Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer

November 11, 2023 | morningstar.com

Aethlon Medical Inc AEMD

November 6, 2023 | finance.yahoo.com

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023

November 1, 2023 | msn.com

Aethlon Medical (AEMD) Price Target Increased by 900.00% to 66.30

October 26, 2023 | markets.businessinsider.com

Promising Oncology Developments and Positive Outlook Propel Aethlon Medical’s Buy Rating

October 25, 2023 | msn.com

HC Wainwright & Co. Maintains Aethlon Medical (AEMD) Buy Recommendation

October 12, 2023 | msn.com

Aethlon Medical receives approval in India for Hemopurifier trial

October 10, 2023 | finance.yahoo.com

Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology

October 5, 2023 | finanznachrichten.de

Aethlon Medical, Inc.: Aethlon Announces Reverse Stock Split

October 5, 2023 | seekingalpha.com

Aethlon Medical to effect 1-for-10 reverse stock split to meet Nasdaq rules

August 30, 2023 | finance.yahoo.com

Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 15, 2023 | markets.businessinsider.com

Maxim Group Sticks to Its Hold Rating for Aethlon Medical (AEMD)

August 14, 2023 | finance.yahoo.com

AEMD: Focusing on Oncology, Infectious Disease & Organ Transplants Initially

August 11, 2023 | finanznachrichten.de

Aethlon Medical, Inc.: Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update

August 10, 2023 | finance.yahoo.com

Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update

August 3, 2023 | msn.com

Aethlon Medical (AEMD) Price Target Decreased by 7.14% to 6.63

August 3, 2023 | finance.yahoo.com

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 10, 2023

See More Headlines

Receive AEMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/10/2023
Today: 12/06/2023
Next Earnings (Estimated): 2/12/2024
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AEMD
CUSIP: N/A
CIK: 773910
Web: www.aethlonmedical.com
Phone: (858) 459-7800
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $23.00
High Stock Price Target: $23.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +995.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,030,000.00
Net Margins: N/A
Pretax Margin: -2,026.66%
Return on Equity: -83.43%
Return on Assets: -69.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.13
Quick Ratio: 6.13

Sales & Book Value

Annual Sales: $570,000.00
Price / Sales: 9.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.56 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 2,490,000
Free Float: 2,393,000
Market Cap: $5.23 million
Optionable: Not Optionable
Beta: 1.46

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Guy F. Cipriani BS (Eng.) (Age 53)
MBA, Chief Operating Officer
Comp: $347.5k
Dr. Steven P. LaRosa M.D. (Age 56)
Chief Medical Officer
Comp: $430k
Mr. James B. Frakes M.B.A. (Age 66)
Interim CEO, CFO, Senior VP of Finance, Secretary & Director
Comp: $385k
Dr. Lee D. Arnold Ph.D. (Age 63)
Chief Scientific Officer

Key Competitors

View All Competitors

AEMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Aethlon Medical stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aethlon Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AEMD shares.
View AEMD analyst ratings or view top-rated stocks.
What is Aethlon Medical's stock price target for 2024?: 1 analysts have issued 1-year price targets for Aethlon Medical's stock. Their AEMD share price targets range from $23.00 to $23.00. On average, they expect the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 995.2% from the stock's current price.
View analysts price targets for AEMD or view top-rated stocks among Wall Street analysts.
How have AEMD shares performed in 2023?: Aethlon Medical's stock was trading at $2.7540 at the start of the year. Since then, AEMD stock has decreased by 23.7% and is now trading at $2.10.
View the best growth stocks for 2023 here.
Are investors shorting Aethlon Medical?: Aethlon Medical saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 127,500 shares, an increase of 26.5% from the October 31st total of 100,800 shares. Based on an average trading volume of 16,100 shares, the short-interest ratio is presently 7.9 days. Currently, 5.3% of the shares of the stock are sold short.
View Aethlon Medical's Short Interest.
When is Aethlon Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our AEMD earnings forecast.
How were Aethlon Medical's earnings last quarter?: Aethlon Medical, Inc. (NASDAQ:AEMD) announced its quarterly earnings results on Thursday, August, 10th. The medical equipment provider reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.10. During the same quarter last year, the business earned ($1.90) earnings per share.

When did Aethlon Medical's stock split?: Aethlon Medical shares reverse split on the morning of Thursday, October 5th 2023. The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Aethlon Medical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Amarin (AMRN), Nokia Oyj (NOK), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), CRISPR Therapeutics (CRSP), Novavax (NVAX), Organigram (OGI), AT&T (T) and Aurora Cannabis (ACB).
Who are Aethlon Medical's major shareholders?: Aethlon Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Aethlon Medical?: Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AEMD) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial